🇺🇸 Levamlodipine besylate in United States

102 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 102

Most-reported reactions

1. Pneumonia — 17 reports (16.67%)
2. Platelet Count Decreased — 12 reports (11.76%)
3. Anaemia — 11 reports (10.78%)
4. Off Label Use — 11 reports (10.78%)
5. Myelosuppression — 10 reports (9.8%)
6. Overdose — 9 reports (8.82%)
7. Decreased Appetite — 8 reports (7.84%)
8. Dizziness — 8 reports (7.84%)
9. Hepatic Function Abnormal — 8 reports (7.84%)
10. Hypokalaemia — 8 reports (7.84%)

Source database →

Frequently asked questions

Is Levamlodipine besylate approved in United States?

Levamlodipine besylate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Levamlodipine besylate in United States?

Jiangsu Simcere Pharmaceutical Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.